Cargando…

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster

Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chin Shern, Thundyil, John, Oh, May Lin Helen, Phua, Soon Kieng, Liang, Ya Li, Li, Yanfeng, Huo, Jianxin, Huang, Yuhan, Zhang, Biyan, Xu, Shengli, Aw, Tar Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680337/
https://www.ncbi.nlm.nih.gov/pubmed/36412836
http://dx.doi.org/10.3390/antib11040070
_version_ 1784834393135644672
author Lau, Chin Shern
Thundyil, John
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
author_facet Lau, Chin Shern
Thundyil, John
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
author_sort Lau, Chin Shern
collection PubMed
description Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab (Roche), IgG (Abbott) and N-Ab (Snibe) levels at set time points from January 2021 to April 2022. All subjects were deemed to be COVID-19-naïve either via clinical history (CoronaVac vaccinees) or nucleocapsid antibody testing (BNT162b2 vaccinees). Results: All antibodies peaked 20–30 days post-inoculation. In BNT162b2 vaccinees, all post-booster antibodies were significantly higher than second-dose peaks. In CoronaVac vaccinees, IgG showed no significant differences between peak third-/second-dose titers (difference of 56.0 BAU/mL, 95% CI of −17.1 to 129, p = 0.0894). The post-vaccination titers of all antibodies in BNT162b2 vaccinees were significantly higher than those in CoronaVac vaccinees at all time points. Post-booster, all antibodies declined in 90 days; the final total/IgG/N-Ab titers were 7536 BAU/mL, 1276 BAU/mL and 12.5 μg/mL in BNT162b2 vaccinees and 646 BAU/mL, 62.4 BAU/mL and 0.44 μg/mL in CoronaVac vaccinees. Conclusion: The mRNA vaccine generated more robust total S-Ab, IgG and N-Ab responses after the second and third vaccinations.
format Online
Article
Text
id pubmed-9680337
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96803372022-11-23 Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster Lau, Chin Shern Thundyil, John Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon Antibodies (Basel) Article Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab (Roche), IgG (Abbott) and N-Ab (Snibe) levels at set time points from January 2021 to April 2022. All subjects were deemed to be COVID-19-naïve either via clinical history (CoronaVac vaccinees) or nucleocapsid antibody testing (BNT162b2 vaccinees). Results: All antibodies peaked 20–30 days post-inoculation. In BNT162b2 vaccinees, all post-booster antibodies were significantly higher than second-dose peaks. In CoronaVac vaccinees, IgG showed no significant differences between peak third-/second-dose titers (difference of 56.0 BAU/mL, 95% CI of −17.1 to 129, p = 0.0894). The post-vaccination titers of all antibodies in BNT162b2 vaccinees were significantly higher than those in CoronaVac vaccinees at all time points. Post-booster, all antibodies declined in 90 days; the final total/IgG/N-Ab titers were 7536 BAU/mL, 1276 BAU/mL and 12.5 μg/mL in BNT162b2 vaccinees and 646 BAU/mL, 62.4 BAU/mL and 0.44 μg/mL in CoronaVac vaccinees. Conclusion: The mRNA vaccine generated more robust total S-Ab, IgG and N-Ab responses after the second and third vaccinations. MDPI 2022-11-08 /pmc/articles/PMC9680337/ /pubmed/36412836 http://dx.doi.org/10.3390/antib11040070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lau, Chin Shern
Thundyil, John
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title_full Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title_fullStr Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title_full_unstemmed Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title_short Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
title_sort neutralizing and total/igg spike antibody responses following homologous coronavac vs. bnt162b2 vaccination up to 90 days post-booster
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680337/
https://www.ncbi.nlm.nih.gov/pubmed/36412836
http://dx.doi.org/10.3390/antib11040070
work_keys_str_mv AT lauchinshern neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT thundyiljohn neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT ohmaylinhelen neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT phuasoonkieng neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT liangyali neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT liyanfeng neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT huojianxin neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT huangyuhan neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT zhangbiyan neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT xushengli neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster
AT awtarchoon neutralizingandtotaliggspikeantibodyresponsesfollowinghomologouscoronavacvsbnt162b2vaccinationupto90dayspostbooster